88 related articles for article (PubMed ID: 12673388)
1. [Influence of deleting 9 amino acid residues at N-terminus on immunogenicity of a Plasmodium falciparum chimeric protein].
Zhang QF; Pan WQ; Qu L; Xue XY
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):345-9. PubMed ID: 12673388
[TBL] [Abstract][Full Text] [Related]
2. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
5. Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.
Daubenberger CA; Nickel B; Ciatto C; Grütter MG; Pöltl-Frank F; Rossi L; Siegler U; Robinson J; Kashala O; Patarroyo ME; Pluschke G
Eur J Immunol; 2002 Dec; 32(12):3667-77. PubMed ID: 12516559
[TBL] [Abstract][Full Text] [Related]
6. High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris.
Brady CP; Shimp RL; Miles AP; Whitmore M; Stowers AW
Protein Expr Purif; 2001 Dec; 23(3):468-75. PubMed ID: 11722185
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
8. Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria.
Peng H; Hu Y; Zhou A; Jin C; Pan W
Malar J; 2010 Mar; 9():76. PubMed ID: 20236549
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites.
Zhang D; Pan W
Infect Immun; 2005 Oct; 73(10):6530-6. PubMed ID: 16177327
[TBL] [Abstract][Full Text] [Related]
10. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate.
Bonnet S; Pêtres S; Holm I; Fontaine T; Rosario S; Roth C; Longacre S
Vaccine; 2006 Aug; 24(33-34):5997-6008. PubMed ID: 16814434
[TBL] [Abstract][Full Text] [Related]
11. Plasmodium falciparum: sequence analysis of the gene encoding the C-terminus region of the merozoite surface protein-1, a potential malaria vaccine antigen, in Iranian clinical isolates.
Mehrizi AA; Zakeri S; Salmanian AH; Sanati MH; Djadid ND
Exp Parasitol; 2008 Mar; 118(3):378-85. PubMed ID: 18053992
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.
Stowers AW; Cioce V; Shimp RL; Lawson M; Hui G; Muratova O; Kaslow DC; Robinson R; Long CA; Miller LH
Infect Immun; 2001 Mar; 69(3):1536-46. PubMed ID: 11179324
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
[TBL] [Abstract][Full Text] [Related]
14. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro.
Pan W; Huang D; Zhang Q; Qu L; Zhang D; Zhang X; Xue X; Qian F
J Immunol; 2004 May; 172(10):6167-74. PubMed ID: 15128804
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.
Reed ZH; Kieny MP; Engers H; Friede M; Chang S; Longacre S; Malhotra P; Pan W; Long C
Vaccine; 2009 Mar; 27(10):1651-60. PubMed ID: 19038302
[TBL] [Abstract][Full Text] [Related]
16. Sequence diversity of the C-terminal region of Plasmodium falciparum merozoite surface protein 1 in southern Iran.
Zamani Z; Razavi MR; Sadeghi S; Naddaf S; Pourfallah F; Mirkhani F; Arjmand M; Feizhaddad H; Rad ME; Tameemi M; Assmar M
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):1-9. PubMed ID: 19323027
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP1(42).
Weiss R; Gabler M; Jacobs T; Gilberger TW; Thalhamer J; Scheiblhofer S
Vaccine; 2010 Jun; 28(28):4515-22. PubMed ID: 20438877
[TBL] [Abstract][Full Text] [Related]
19. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
[TBL] [Abstract][Full Text] [Related]
20. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes.
Hui G; Hashimoto C
Vaccine; 2007 Jan; 25(5):948-56. PubMed ID: 17023096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
